Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Affiliations

• ¹ NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
• ² Mayo Clinic, Rochester, MN, USA.
• ³ University Hospital Halle, Halle, Germany.
• ⁴ Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
• ⁵ Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), Leuven, Belgium.
• ⁶ Medizinische Universität Wien, Vienna, Austria.
• ⁷ Peking University, People's Hospital, Beijing, China.
• ⁸ Hôpital Saint-Louis, Paris, France.
• ⁹ Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA.
• ¹⁰ University of Insubria, Varese, Italy.
• ¹¹ Cancer Campus, 11 Gustave Roussy, Villejuif, France.
• ¹² Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
• ¹³ Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
• ¹⁴ Peking Union Medical College Hospital, Beijing, China.
• ¹⁵ Queens University Belfast, Belfast, UK.
• ¹⁶ Bristol-Myers Squibb, New Brunswick, NJ, USA.
• ¹⁷ Haematology Research Centre, Imperial College London, London, UK.
• ¹⁸ NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. Adam.mead@imm.ox.ac.uk.